Journal Guide
Publishing in Annals of Oncology: Fit, Timeline & Submission Guide
Oncology: clinical trials, cancer biology, and therapeutic innovation
Should you submit here?
Submit if present trial or finding improving cancer patient survival or outcomes. Be careful if aO expects mature, significant clinical data.
65.4
Impact Factor (2024)
~10-20%
Acceptance Rate
~90-120 days median
Time to First Decision
Submission guide
Annals of Oncology Submission Guide: Requirements & What Editors Want
A practical Annals of Oncology submission guide covering package readiness, editorial priority signals, and what to fix before upload.
Journal assessment
Is Annals of Oncology a Good Journal? A Practical Fit Verdict
A practical Annals of Oncology fit verdict for authors deciding whether their study is clinically important enough for the ESMO flagship oncology journal.
Desk rejection
How to Avoid Desk Rejection at Annals of Oncology (2026)
What Annals of Oncology editors screen for before peer review, and the missing pieces that make an oncology paper look promising but still too early.
What Ann. Oncol. Publishes
Annals of Oncology published by ESMO is a premier international oncology journal. With JIF 65.4 and Q1 ranking in Oncology, AO emphasizes high-impact cancer research combining clinical findings with mechanistic insight. The journal publishes research on cancer treatment, biomarkers, and clinical outcomes. Critically: AO is highly selective, valuing work advancing cancer treatment globally. Routine studies lack competitiveness. The journal seeks papers making major oncology contributions.
- Clinical trial outcomes: treatment efficacy, safety, response prediction
- Cancer immunotherapy: checkpoint inhibitors, cellular therapy, immune mechanisms
- Precision oncology: genomic testing, biomarkers, treatment selection
- Solid tumors: lung, breast, colorectal, ovarian, gastric cancers
- Hematologic malignancies: leukemia, lymphoma, myeloma
- Novel therapies: antibody-drug conjugates, CAR-T, targeted therapies
- Resistance mechanisms: drug resistance, combination strategies, overcoming resistance
- Cancer biology: tumor microenvironment, immune infiltration, disease mechanisms
Editor Insight
“Annals of Oncology publishes high-impact cancer research advancing global oncology practice. We seek mature clinical trials with significant efficacy and mechanistic insight.”
What Ann. Oncol. Editors Look For
High-impact clinical finding advancing cancer treatment outcomes
Present trial or finding improving cancer patient survival or outcomes. New treatment benefit? Superior biomarker? Prevention strategy? Major clinical impact required.
Rigorous trial design with adequate patient numbers and follow-up
Randomized clinical trials or large translational studies. Sufficient power and mature follow-up for clinical endpoints.
Mechanistic understanding of treatment response or resistance
Explain why therapy works or why resistance emerges. Molecular mechanisms driving clinical outcomes.
Biomarker validation predicting treatment response
Biomarkers validated in independent cohorts enabling patient stratification and treatment selection.
Global applicability and real-world relevance
Show treatment feasible and effective across healthcare systems. Address practical implementation.
Why Papers Get Rejected
These patterns appear repeatedly in manuscripts that don't make it past Ann. Oncol.'s editorial review:
Phase 1/2 trial without mature efficacy data
AO expects mature, significant clinical data. Early-phase work without clear efficacy signal or mechanism insufficient.
Single-center study without multi-center validation
Single-site findings need independent validation. Multi-center trials strengthen credibility.
No mechanistic explanation of treatment effect
Explain treatment mechanisms. What drives response? What predicts resistance?
Biomarker claims without independent validation
Biomarkers must validate in independent cohorts. Single-cohort discovery insufficient.
Ignoring global context and healthcare disparities
Show treatment applicable globally. Address cost and accessibility issues.
Does your manuscript avoid these patterns?
The Free Readiness Scan reads your full manuscript against Ann. Oncol.'s criteria and flags the specific issues most likely to cause rejection.
Insider Tips from Ann. Oncol. Authors
Randomized phase 3 trials with survival endpoints most competitive
Mature, powered trials showing overall survival or progression-free survival benefit have highest impact.
Immunotherapy combination and sequencing increasingly valued
Optimizing checkpoint inhibitor combinations and treatment sequences increasingly important.
Predictive biomarkers for treatment selection competitive
Biomarkers enabling precise treatment selection have immediate clinical utility.
Resistance mechanisms and overcoming resistance valued
Understanding and overcoming therapeutic resistance increasingly important as field matures.
Patient-reported outcomes and quality of life emphasized
Patient-centered outcomes increasingly important in modern oncology trials.
The Ann. Oncol. Submission Process
Manuscript preparation
Prep6,000-9,000 words with 6-8 figures. Include trial design, patient cohort, treatment description, efficacy/safety outcomes, biomarker analysis, mechanistic discussion.
Submission via ESMO system
Day 0Submit at https://www.annalsofoncology.org/. Required: manuscript emphasizing clinical significance, figures showing efficacy and biomarker data, cover letter highlighting impact.
Editorial assessment
1-2 weeksEditor assesses trial significance and oncology impact. Routine studies or early-phase work face rejection. Highly selective desk rejection ~50-60%.
Peer review
90-120 days2-3 leading oncologists assess trial design rigor, outcome significance, mechanistic insight, biomarker validity, and global applicability. First decision 90-120 days.
Revision and publication
Revision: 2-4 weeksRevisions often minor if accepted. Publication 2-4 weeks after acceptance.
Ann. Oncol. by the Numbers
| 2024 Impact Factor | 14.3 |
| 5-Year Impact Factor | 14.9 |
| Acceptance rate | ~10-20% |
| Desk rejection rate | ~50-60% |
| Median first decision | ~105 days |
| Open access option | $4,500 USD |
| Publisher | ESMO |
| Founded | 1990 |
Before you submit
Ann. Oncol. accepts a small fraction of submissions. Make your attempt count.
Start with the Free Readiness Scan. Unlock the Full AI Diagnostic for $29. If you need deeper scientific feedback, choose Expert Review. The full report is calibrated to Ann. Oncol..
Article Types
Clinical Trial
6,000-9,000 wordsPhase 2-3 cancer trial with efficacy outcomes
Translational Research
6,000-9,000 wordsCancer biology with clinical application
Landmark Ann. Oncol. Papers
Papers that defined fields and changed science:
- Checkpoint inhibitor trials (2015+) - immunotherapy revolution
- Targeted therapy in advanced cancer (2010s+) - precision oncology
- Novel combination therapies (2010s+) - overcoming resistance
- Biomarker-driven trial designs (2010s+) - patient stratification
Preparing a Ann. Oncol. Submission?
Get pre-submission feedback from reviewers who've published in Ann. Oncol. and know exactly what editors look for.
Run Free Readiness ScanNeed expert depth? See Expert Review Options
Primary Fields
Browse by Field
Related Journal Guides
- Publishing in Nature
- Publishing in The Lancet
- Publishing in JAMA (Journal of the American Medical Association)
- Publishing in Journal of Clinical Oncology
- Publishing in The Lancet Oncology
Latest Journal-Specific Guides
- Submission guideAnnals of Oncology Submission Guide: Requirements & What Editors WantA practical Annals of Oncology submission guide covering package readiness, editorial priority signals, and what to fix before upload.
- Journal assessmentIs Annals of Oncology a Good Journal? A Practical Fit VerdictA practical Annals of Oncology fit verdict for authors deciding whether their study is clinically important enough for the ESMO flagship oncology journal.
- Desk rejectionHow to Avoid Desk Rejection at Annals of Oncology (2026)What Annals of Oncology editors screen for before peer review, and the missing pieces that make an oncology paper look promising but still too early.
- Review timelineAnnals of Oncology Review Time: What Authors Can Actually ExpectAnnals of Oncology moves quickly on low-priority papers, but manuscripts that clear triage still face a selective multi-week oncology review path.
More Guides for This Journal
- Acceptance rateAnnals of Oncology Acceptance Rate: What Authors Can UseAnnals of Oncology does not publish a strong official acceptance rate. The better submission question is whether the paper is broad and mature enough to matter at ESMO-flagship level.
- Impact factorAnnals of Oncology Impact Factor 2026: Ranking, Quartile & What It MeansAnnals of Oncology impact factor is 65.4. Five-year JIF 46.8, Q1, rank 4/326. See trend, comparisons, and submission guidance.
- Publishing costsAnnals of Oncology APC and Open Access: Current ESMO Pricing, Agreement Rules, and When Gold OA Is Worth ItAnnals of Oncology APC is EUR 5,556. Hybrid ESMO pricing, 12-month embargo rules, agreement coverage, and oncology fit guidance.
- Submission processAnnals of Oncology Submission Process: What Happens From Upload to First DecisionA practical Annals of Oncology process guide covering what happens after upload, what editors test first, and where oncology papers lose momentum.
- Manuscript prepAnnals of Oncology Cover Letter: What Editors Actually Need to SeeAnnals of Oncology editors are screening for practice-relevant oncology evidence, not just interesting cancer data. A strong cover letter makes the treatment consequence obvious fast.
- Publishing guideAnnals of Oncology Formatting Requirements: Complete Author GuideAnnals of Oncology limits Original Articles to 3,000 words with a 250-word structured abstract and up to 6 figures/tables combined. References use Vancouver numbered style with square brackets, and CONSORT compliance is required for clinical trials.
Ready to submit to Ann. Oncol.?
A desk rejection costs months. Get expert feedback before you submit, from scientists who know exactly what Ann. Oncol. editors look for.
Avoid Desk Rejection
Get expert pre-submission review before you submit to Ann. Oncol.. 3-7 day turnaround.
Manuscript Rejected?
Expert revision help to strengthen your manuscript and resubmit with confidence.
Reviewer Response Help
Get expert guidance crafting your response to Ann. Oncol. reviewers.
Reference library
Compare Ann. Oncol. with the broader publishing context
This journal guide is the best starting point for Ann. Oncol.. The reference library covers the surrounding questions authors usually ask next: whether the package is ready, what drives desk rejection, how neighboring journals compare, and what the submission constraints look like across the field.
Checklist system / operational asset
Elite Submission Checklist
A flagship pre-submission checklist that turns journal-fit, desk-reject, and package-quality lessons into one operational final-pass audit.
Flagship report / decision support
Desk Rejection Report
A canonical desk-rejection report that organizes the most common editorial failure modes, what they look like, and how to prevent them.
Dataset / reference hub
Journal Intelligence Dataset
A canonical journal dataset that combines selectivity posture, review timing, submission requirements, and Manusights fit signals in one citeable reference asset.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Need field-expert depth? See Expert Review Options